High analytical sensitivity with lower detection limits
The EZ1 DSP Virus Kit provides simultaneous purification of viral nucleic acids and bacterial DNA from human serum, plasma, CSF, urine, whole blood, stool, transport media, respiratory samples, and dried swab. Efficient purification of viral RNA and DNA results in sensitive analytical detection in polymerase chain reaction (PCR), as demonstrated using CE-IVD-marked artus PCR Kits for detection of CMV DNA (see table "Detection limit of CMV DNA using the EZ1 DSP Virus system and artus CMV PCR Kits") and HBV DNA (see table "Detection limit of HBV DNA using the EZ1 DSP Virus system and artus HBV PCR Kits") on a variety of real-time thermal cyclers.
1000 | 18/18 | 18/18 | 6/6 |
316 | 15/15 | 15/15 | 18/18 |
100 | 23/24 | 24/24 | 18/18 |
31.6 | 30/33 | 27/27 | 18/18 |
15.8 | 10/18 | 11/12 | 18/18 |
10 | 12/36 | 21/36 | 34/36 |
7.9 | 8/18 | 7/18 | 15/18 |
5.0 | 4/18 | 11/18 | 13/18 |
3.16 | 2/18 | 6/18 | 26/36 |
1 | 0/18 | 1/18 | 4/18 |
0.316 | 1/18 | 0/18 | 1/18 |
0.1 | 1/18 | 1/18 | 0/18 |
0 | 0/6 | 0/6 | 0/18 |
95% probit value (copies/ml) | 67.2 | 21.8 | 13.2 |
Confidence interval (copies/ml) | 41.8–142 | 14.5–44.1 | 9.0–23.1 |
1000 | 6/6 | 12/12 | 18/18 |
316 | 18/18 | 18/18 | 15/15 |
100 | 18/18 | 18/18 | 24/24 |
31.6 | 18/18 | 18/18 | 32/33 |
15.8 | 10/18 | 18/18 | 16/18 |
10 | 13/36 | 34/36 | 26/36 |
7.9 | 9/18 | 15/17 | 13/18 |
5.0 | 4/18 | 13/18 | 9/18 |
3.16 | 5/36 | 23/36 | 7/18 |
1 | 1/18 | 5/15 | 5/18 |
0.316 | 0/18 | 2/17 | 2/18 |
0.1 | 0/18 | 1/18 | 2/18 |
0 | 0/18 | 0/18 | 0/6 |
95% probit value (copies/ml) | 45.7 | 14.4 | 38.3 |
Confidence interval (copies/ml) | 28–102 | 9.5–26.5 | 21.5–89.8 |
Linear yields of highly pure viral DNA and RNA
Purification of viral nucleic acids provides linear yields, allowing accurate quantitative analysis for both high and low viral titers. Purified viral nucleic acids give high-performance results in sensitive diagnostic assays, even when starting material contains elevated levels of endogenous inhibitors, demonstrating the robustness of the purification procedure (see table "Robust purification procedure provides unparalleled removal of inhibitors").
Untreated | – | 2.87 | 0.04 |
Bilirubin | 20 mg/dl | 2.83 | 0.02 |
Hemoglobin | 500 mg/dl | 2.80 | 0.09 |
Protein | 9 g/dl | 2.77 | 0.06 |
Liposyn | 3000 mg/dl | 2.80 | 0.06 |
Exclusion of sample carryover
High process reliability is critical for clinical laboratories that purify nucleic acids for routine testing. Lack of sample-to-sample carryover is a prerequisite for reliable results. To evaluate the risk of sample-to-sample carryover during and between runs, the EZ1 DSP Virus procedure was subjected to rigorous testing using an alternating checkerboard setup of negative and highly positive (1.0 x 108 IU/ml) parvovirus B19 DNA samples. All of the highly positive samples were detected positive using the CE-IVD-marked artus Parvo B19 RG PCR Kit. All negative samples, in the checkerboard runs and the all-negative runs, were unresponsive (see table "Cross-contamination test setup and CT values for detection of parvovirus B19 DNA"). This demonstrates that the EZ1 DSP Virus procedure provides no sample carryover under these conditions.
1 | 15.47 | X | 15.41 | X | 15.36 | X |
2 | X | 15.48 | X | 15.53 | X | 15.32 |
3 | X | X | X | X | X | X |
4 | 15.35 | X | 15.20 | X | 15.27 | X |
5 | X | 15.21 | X | 15.13 | X | 15.42 |
6 | X | X | X | X | X | X |
7 | 15.X2 | X | 15.48 | X | 15.23 | X |
8 | X | 15.31 | X | 15.83 | X | 15.62 |
9 | X | X | X | X | X | X |